4/A: OpGen Inc. Director David E. Lazar Acquires Additional Series E Convertible Preferred Stock

Sentiment:

SEC Form 4/A


David E. Lazar, a director and 10% owner of OpGen Inc., acquired an additional 200,000 shares of Series E Convertible Preferred Stock on April 5, 2024, as part of a larger securities purchase agreement.

Summary

  • David E. Lazar, a director, 10% owner, and CEO of OpGen Inc., filed an amended Form 4/A to report changes in beneficial ownership.
  • On April 5, 2024, Lazar acquired 200,000 shares of Series E Convertible Preferred Stock at $1.00 per share, totaling $200,000.
  • This acquisition is part of a securities purchase agreement entered into on March 25, 2024, where Lazar will acquire an aggregate of 3,000,000 shares of Series E Preferred Stock.
  • Each share of Series E Preferred Stock is convertible into 24 shares of OpGen's Common Stock, subject to certain ownership limitations.
  • The reported number of shares of Common Stock underlying the shares of Series E Preferred Stock has been adjusted to reflect a reverse stock split of the Company's Common Stock effective as of May 20, 2024.
  • The Series E Preferred Stock is perpetual and therefore has no expiration date.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive as a director is increasing their stake in the company, which can be seen as a vote of confidence. However, the context of the purchase agreement and potential future conditions temper the enthusiasm.

Positives

  • A director and significant shareholder is increasing their investment in the company, signaling confidence.

Future Outlook

The Reporting Person will acquire additional shares of Series E Preferred Stock at subsequent closings, subject to certain conditions being satisfied.

Industry Context

Insider transactions are closely watched as indicators of management's confidence in the company's prospects. Significant purchases by insiders can be viewed positively by the market.

Related Party Transactions

  • The securities purchase agreement between OpGen, Inc. and David E. Lazar, a director and officer, constitutes a related party transaction.

Stakeholder Impact

  • Shareholders may view the insider purchase positively.
  • The capital injection could potentially benefit the company's operations and growth.

Next Steps

  • David E. Lazar will acquire additional shares of Series E Preferred Stock at subsequent closings, subject to certain conditions being satisfied.

Key Dates

DateDescription
March 25, 2024Date of the securities purchase agreement between David E. Lazar and OpGen, Inc.
April 5, 2024Date of additional closing where David E. Lazar acquired 200,000 shares of Series E Preferred Stock.
April 8, 2024Date of Original Filed
May 20, 2024Effective date of the reverse stock split of OpGen's Common Stock.
July 31, 2024Date of signature on the Form 4/A.

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.